Immunotherapy updates in GI cancer

Gastrointestinal (GI) cancers have a high incidence rate and is the leading cause of cancer-related mortality. Despite current combinational treatment strategies including chemotherapy, surgery, radiotherapy, and targeted therapies, survival rates remain markedly low for patients with advanced disease due to treatment resistance, rapid disease progression and metastasis, creating a strong urgency for the development of optimal therapeutic approaches. Immunotherapy is becoming increasingly established in the integrative management of GI cancers, with novel combinational strategies revolutionizing the treatment landscape and providing promise for patients with advanced stage disease. In this podcast we hear from Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, Eran Ophir, PhD, Compugen Ltd., Tel Aviv, Israel, Michael Overman, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Andras Heczey, MD, Baylor College of Medicine, Houston, TX, and Mitchell Ho, PhD, National Institutes of Health, Bethesda, MD, on some of the latest immunotherapeutic strategies for treating GI cancers.